Veliparib
Showing 1 - 25 of 97
Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound,
No longer available
- Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound
- +3 more
- Veliparib
- (no location specified)
May 20, 2022
Metastatic Triple Negative Breast Cancer Trial in Birmingham (Combination of Veliparib + Lapatinib)
Active, not recruiting
- Metastatic Triple Negative Breast Cancer
- Combination of Veliparib + Lapatinib
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Feb 25, 2022
Malignant Solid Tumor Trial in United States (drug, other, procedure)
Active, not recruiting
- Malignant Solid Neoplasm
- Ferumoxytol
- +4 more
-
Baltimore, Maryland
- +5 more
Nov 8, 2022
Cancer - Ovarian Trial (Veliparib, capsule, Veliparib, tablet, Carboplatin)
Withdrawn
- Cancer - Ovarian
- Veliparib, capsule
- +3 more
- (no location specified)
Dec 6, 2021
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid
Active, not recruiting
- Acute Myeloid Leukemia
- +9 more
- Carboplatin
- +3 more
-
Los Angeles, California
- +5 more
Jan 27, 2023
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma Trial in
Active, not recruiting
- Locally Advanced Pancreatic Adenocarcinoma
- +4 more
- Biopsy
- +4 more
-
Chicago, Illinois
- +11 more
Jun 28, 2022
Tumors Trial in Bethesda, Boston, Houston (Veliparib + VX-970 + Cisplatin)
Completed
- Neoplasms
- Veliparib + VX-970 + Cisplatin
-
Bethesda, Maryland
- +2 more
Jan 14, 2022
Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Solid Tumor Trial in New Brunswick
Active, not recruiting
- Ann Arbor Stage III Non-Hodgkin Lymphoma
- +2 more
- Cyclophosphamide
- +4 more
-
New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
Jan 28, 2023
Advanced Solid Tumors Trial (veliparib (ABT-888), carboplatin, gemcitabine)
Completed
- Advanced Solid Tumors
- veliparib (ABT-888)
- +2 more
- (no location specified)
Jul 29, 2021
Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation, Triple-Negative Breast Cancer Trial in Seattle (Veliparib,
No longer available
- Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation
- Triple-Negative Breast Cancer
- Veliparib
- +2 more
-
Seattle, WashingtonSeattle Cancer Care Allliance
Jul 14, 2021
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Active, not recruiting
- Acute Lymphoblastic Leukemia
- +15 more
- Laboratory Biomarker Analysis
- +3 more
-
Chicago, Illinois
- +2 more
Jan 12, 2023
Metastatic Malignant Solid Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma Trial in United States
Active, not recruiting
- Metastatic Malignant Solid Neoplasm
- +4 more
- Laboratory Biomarker Analysis
- +4 more
-
Phoenix, Arizona
- +14 more
Sep 1, 2022
Testicular Cancer Trial in Bratislava (Veliparib, Gemcitabine, Carboplatin)
Completed
- Testicular Cancer
- Veliparib
- +2 more
-
Bratislava, SlovakiaNational Cancer Institute
Mar 2, 2021
Pancytopenia Related to PARP Inhibitors (PancytoRIB)
Completed
- Cancer
- PARP inhibitor
-
Caen, Basse Normandie, FranceAlexandre Joachim
Sep 16, 2021
Breast Cancer, Metastatic Breast Cancer, BRCA1 Gene Mutation Trial in Boston (ABT-888, temozolomide)
Active, not recruiting
- Breast Cancer
- +3 more
-
Boston, Massachusetts
- +2 more
Dec 21, 2022
Small Cell Lung Cancer SCLC Trial in München Gauting (veliparib, Topotecan)
Recruiting
- Small Cell Lung Cancer SCLC
- veliparib
- Topotecan
-
München Gauting, GermanyKlinik München Gauting
Jan 26, 2021
Gastric Cancer Trial in Korea, Republic of, United States (Veliparib)
Completed
- Gastric Cancer
- Veliparib
-
Scottsdale, Arizona
- +7 more
Jul 29, 2021
Pulmonary Toxicities Related to PARP Inhibitors (PulmonaRIB)
Recruiting
- Cancer
- olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib
-
Caen, Basse Normandie, FranceAlexandre Joachim
May 27, 2021
Advanced Solid Tumor, Aggressive Non-Hodgkin Lymphoma, Recurrent Solid Tumor Trial in Chicago (other, biological, drug)
Unknown status
- Advanced Solid Neoplasm
- +5 more
- Laboratory Biomarker Analysis
- +3 more
-
Chicago, IllinoisNorthwestern University
Oct 27, 2020
Pancreatic Cancer Trial in Los Angeles (Veliparib, Gemcitabine, Intensity modulated radiation therapy)
Completed
- Pancreatic Cancer
- Veliparib
- +2 more
-
Los Angeles, CaliforniaCedars-Sinai Medical Center
Jul 13, 2020
Advanced Malignant Solid Tumor Trial in United States (Adavosertib, Carboplatin, Everolimus)
Completed
- Advanced Malignant Solid Neoplasm
- Adavosertib
- +5 more
-
Aurora, Colorado
- +7 more
Apr 11, 2022
NSCLC Stage III Trial in United States (Paclitaxel, Placebo for Veliparib, Carboplatin)
Terminated
- Non-small Cell Lung Cancer Stage III
- Paclitaxel
- +4 more
-
La Jolla, California
- +11 more
Jul 8, 2020
Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma Trial in Worldwide (Radiation Therapy, Temozolomide, Veliparib)
Active, not recruiting
- Anaplastic Astrocytoma
- +2 more
- Radiation Therapy
- +2 more
-
Birmingham, Alabama
- +162 more
Dec 30, 2022
Castration-Resistant Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7 Trial in United States
Completed
- Castration-Resistant Prostate Carcinoma
- +2 more
- Abiraterone Acetate
- +3 more
-
Duarte, California
- +13 more
Oct 21, 2020
Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC
Completed
- Stage IV Fallopian Tube Cancer AJCC v6 and v7
- +2 more
- Floxuridine
- +3 more
-
Scottsdale, Arizona
- +4 more
Jul 1, 2020